Back to News
Market Impact: 0.25
Nxera Pharma To Support Phase 3 Development Of Fabry Disease Candidate; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Nxera Pharma exercised its option to license lucerastat from Idorsia, obtaining exclusive development and commercialization rights in Japan, South Korea, Taiwan, and selected other Asia Pacific markets. China is excluded; no financial terms or development milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft's Big Bets on AI Start to Pay Off
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off